Hims House Ep 38 - HIMS WEEK IN REVIEW: Bloomberg, WaPo, Canada, Blood Tests, Nighthawk, and 38% Short Interest 🤯
Jul 16, 2025
The hosts delve into major media coverage, including a notable piece in Bloomberg Businessweek and the Washington Post's take on recent corporate upheaval. They explore Hims' ambitious expansion into Canada with generic medications, alongside the emergence of a new blood diagnostics division. Key insights on financial trends and app performance are highlighted, while a staggering 38% short interest raises eyebrows. The analysis touches on market dynamics and the complexities surrounding recent partnerships, packing this discussion with financial intrigue.
AI Snips
Chapters
Transcript
Episode notes
Bloomberg Article Lacks Depth
- The Bloomberg Businessweek article on Hims emphasized meme stock traders but lacked any substantial new information.
- Patrick Lester felt the story was predictable and didn't cast any party in a favorable light.
Hims' Canada Strategy Explained
- Hims expanded into Canada to sell generic semaglutide after patent expiry instead of acquiring local telehealth companies.
- They prefer taking customers from competitors organically rather than through acquisitions.
Sudden Collapse of Novo-Hims Deal
- The Novo-Hims deal collapsed suddenly likely due to board-level decisions at Novo rather than the U.S. team.
- Both Hims and Novo's American teams were likely caught off guard by the abrupt termination.